Highlights:,Cologuard Plus™ outperforms other noninvasive screening ... sed do eiusmod tempor incididunt ut labore et dolore ...

Enter Cologuard, the at-home colon cancer screening test for people aged 45 and older. Perhaps best known by audiences for its cheeky approach to advertising, the Exact Sciences brand recently ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Exact Sciences is a leading provider of diagnostic testing and a maker of the noninvasive colorectal cancer screening test Cologuard ... Dr. Inan Dogan. • Ad-Free Browsing: Enjoy a year ...

The Cologuard Plus test is now approved ... for Geneoscopy’s future infringement and false advertising. MADISON, Wis., May 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider ...

The Cologuard Plus test is now approved for adults ... Sciences to seek relief for Geneoscopy’s future infringement and false advertising. MADISON, Wis., May 08, 2024--Exact Sciences Corp. (Nasdaq: ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

At this time, I would like to welcome everyone to the Exact Sciences. Third quarter ... 1.2 million patients including a record number with Cologuard and Etty DX. Growing total revenue 13% ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.